Quick Answer
ARS Pharmaceuticals, Inc. reported Operating Income of -$179.45 million for fiscal year 2025.
ARS Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$179.45M | -5720.6% |
| 2024 | -$3.08M | +95.4% |
| 2023 | -$67.52M | -90.1% |
| 2022 | -$35.52M | -82.6% |
| 2021 | -$19.45M | +40.9% |
| 2020 | -$32.92M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$53.19M | -144.6% | -11.7% |
| June 30, 2025 | -$47.61M | -210.4% | -28.1% |
| March 31, 2025 | -$37.18M | -181.8% | -70.9% |
| September 30, 2024 | -$21.75M | -21.0% | -41.8% |
| June 30, 2024 | -$15.34M | +25.5% | -16.3% |
| March 31, 2024 | -$13.19M | +29.5% | +26.6% |
| September 30, 2023 | -$17.98M | -171.2% | +12.7% |
| June 30, 2023 | -$20.60M | -224.8% | -10.1% |
- ARS Pharmaceuticals, Inc. showed a decrease of -5720.6% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, ARS Pharmaceuticals, Inc.’s operating income has declined by 445.1% (from -$32.92 million to -$179.45 million).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: